文献速递湿疹皮炎与荨麻疹

巴瑞替尼治疗中重度特应性皮炎缓解者的长期疗效:两项随机临床试验的扩展研究

Long-term Efficacy of Baricitinib in Adults With Moderate to Severe Atopic Dermatitis Who Were Treatment Responders or Partial Responders: An Extension Study of 2 Randomized Clinical Trials.
PubMed 文献 · JAMA Dermatol · 2021-01-01

BREEZE-AD3是BREEZE-AD1/AD2完成后进行的多中心双盲长期扩展研究,评估巴瑞替尼4mg和2mg在中重度特应性皮炎应答或部分应答患者中的68周疗效。结果显示vIGA-AD(0,1)、EASI75和瘙痒NRS改善在长期治疗中得以维持,提示巴瑞替尼具有持续长期疗效。

要点

  • 巴瑞替尼4mg组第16周vIGA-AD(0,1)为45.7%,第68周为47.1%。
  • 巴瑞替尼2mg组第16周vIGA-AD(0,1)为46.3%,第68周为59.3%。
  • 瘙痒NRS改善≥4分在4mg组第16周为52.5%,第32周为45.9%。

核心结论

  • 巴瑞替尼4mg和2mg在中重度特应性皮炎应答或部分应答患者中显示出持续的长期疗效。

研究设计与样本

  • BREEZE-AD1/AD2完成后的多中心双盲长期扩展研究BREEZE-AD3,纳入应答或部分应答患者,继续原治疗52周(累计68周连续治疗)。
  • 巴瑞替尼4mg组n=70,平均年龄36.7岁,男性42例(60%);2mg组n=54,平均年龄32.8岁,男性28例(51.9%)。
  • 主要终点为BREEZE-AD3第16、36、52周达到vIGA-AD(0,1)的患者比例;缺失数据采用末次观测结转,改良意向治疗分析。

主要发现

  • 4mg组达到vIGA-AD(0,1)的比例第16周为45.7%,第68周为47.1%。
  • 4mg组EASI75第16周为70.0%,第68周为55.7%;瘙痒NRS改善≥4分第16周为52.5%,第32周为45.9%。
  • 2mg组达到vIGA-AD(0,1)的比例第16周为46.3%,第68周为59.3%。
  • 2mg组EASI75第16周为74.1%,第68周为81.5%;瘙痒NRS改善≥4分第16周为44.2%,第32周为39.5%。

临床怎么用

  • 对巴瑞替尼诱导治疗应答或部分应答的中重度特应性皮炎患者,可考虑继续长期治疗以维持疗效。

局限性

  • 本研究为扩展研究,仅纳入完成母研究的应答或部分应答患者,缺失数据采用末次观测结转。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Baricitinib, an oral selective Janus kinase inhibitor, improved the clinical signs and symptoms of moderate to severe atopic dermatitis in the 16-week, phase 3 monotherapy studies, BREEZE-AD1 and BREEZE-AD2. Long-term efficacy has not yet been examined. OBJECTIVE: To evaluate the long-term (68-week) efficacy of baricitinib in adults with moderate to severe atopic dermatitis who were treatment responders or partial responders in BREEZE-AD1 and BREEZE-AD2. DESIGN, SETTING, AND PARTICIPANTS: Patients completing BREEZE-AD1/BREEZE-AD2 entered the ongoing, multicenter, double-blind, long-term extension study BREEZE-AD3. The study was initiated on March 28, 2018. Data were analyzed on December 13, 2019. INTERVENTIONS: Responders and partial responders (patients achieving validated Investigator Global Assessment for Atopic Dermatitis [vIGA-AD] score of 0 or 1 [0,1], or 2) at BREEZE-AD1/BREEZE-AD2 completion remained on originally assigned treatment for 52 weeks (68 total weeks of continuous therapy). MAIN OUTCOMES AND MEASURES: The primary end point was the proportion of patients achieving a vIGA-AD score of 0,1 at weeks 16, 36, and 52 of BREEZE-AD3. Secondary end points included the proportion of patients achieving 75% or more improvement in the Eczema Area and Severity Index [EASI75] score and 4-point or more improvement in the itch numeric rating scale (NRS), using originating study baseline data. Itch data were collected during the first 16 weeks in BREEZE-AD3. The last originating study visit was the first BREEZE-AD3 visit; therefore, data are presented for continuous weeks of therapy, including the 16-week originating study period. Missing data were imputed by last observation carried forward. Modified intention-to-treat analysis was used. RESULTS: Of the responder/partial responder population, the proportion of patients treated with baricitinib, 4 mg (n = 70) (mean [SD] age, 36.7 [15.5] years; 42 [60%] were men), achieving vIGA-AD (0,1) at week 16 was 45.7% (BREEZE-AD3 baseline) and, at week 68, 47.1%. Improvement of 75% or more in the EASI score was 70.0% at week 16 and 55.7% at week 68. The proportion of patients achieving an itch NRS improvement greater than or equal to 4 points at week 16 was 52.5% and, at week 32, 45.9%. Of the responder/partial responder population, the proportion of patients treated with baricitinib, 2 mg (n = 54) (mean [SD] age, 32.8 [12.7] years; 28 [51.9%] were men), achieving vIGA-AD (0,1) at week 16 was 46.3% and, at week 68, 59.3%. Improvement in the EASI75 score was 74.1% at week 16 and 81.5% at week 68. The proportion of patients achieving an itch NRS improvement greater than or equal to 4 points at week 16 was 44.2% and, at week 32, 39.5%. CONCLUSIONS AND RELEVANCE: In this long-term double-blind extension study of 2 randomized clinical trials, baricitinib, 4 and 2 mg, demonstrated sustained long-term efficacy in patients with moderate to severe atopic dermatitis. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03334435.

来源:JAMA Dermatol,查看原文。版权归原作者所有。

引用

  1. Silverberg JI, Simpson EL, Wollenberg A, et al. Long-term Efficacy of Baricitinib in Adults With Moderate to Severe Atopic Dermatitis Who Were Treatment Responders or Partial Responders: An Extension Study of 2 Randomized Clinical Trials. JAMA Dermatol. 2021. PMID: 33978711. doi:10.1001/jamadermatol.2021.1273

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。